Oxford Immunotec Global (NASDAQ:OXFD) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Other equities analysts also recently issued reports about the stock. Cowen cut their price target on shares of Oxford Immunotec Global from $22.00 to $19.00 and set an “outperform” rating on the stock in a report on Thursday, August 17th. Piper Jaffray Companies cut their price target on shares of Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating on the stock in a report on Tuesday, October 31st. Zacks Investment Research downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a report on Saturday, November 4th. BTIG Research began coverage on shares of Oxford Immunotec Global in a report on Thursday, September 28th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, ValuEngine downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a report on Tuesday, October 31st. Three equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Oxford Immunotec Global currently has a consensus rating of “Hold” and a consensus price target of $19.75.

Oxford Immunotec Global (NASDAQ:OXFD) opened at $13.63 on Friday. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.38. Oxford Immunotec Global has a fifty-two week low of $12.19 and a fifty-two week high of $19.51.

In related news, CEO Peter Wrighton-Smith sold 55,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $16.78, for a total value of $922,900.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $13.35, for a total value of $40,050.00. Following the completion of the sale, the director now owns 17,778 shares in the company, valued at $237,336.30. The disclosure for this sale can be found here. 8.11% of the stock is currently owned by insiders.

A number of institutional investors have recently made changes to their positions in OXFD. Voya Investment Management LLC raised its stake in Oxford Immunotec Global by 16.0% in the 2nd quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock valued at $224,000 after acquiring an additional 1,845 shares during the period. Alliancebernstein L.P. bought a new stake in Oxford Immunotec Global in the 2nd quarter valued at about $247,000. Asymmetry Capital Management L.P. bought a new stake in Oxford Immunotec Global in the 2nd quarter valued at about $273,000. The Manufacturers Life Insurance Company raised its stake in Oxford Immunotec Global by 8.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock valued at $313,000 after acquiring an additional 1,500 shares during the period. Finally, Rhumbline Advisers raised its stake in Oxford Immunotec Global by 9.1% in the 2nd quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock valued at $412,000 after acquiring an additional 2,053 shares during the period. Institutional investors and hedge funds own 89.35% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “BidaskClub Downgrades Oxford Immunotec Global (OXFD) to Sell” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/bidaskclub-downgrades-oxford-immunotec-global-oxfd-to-sell/1756571.html.

About Oxford Immunotec Global

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.